{"product_id":"syk-ansoff-matrix","title":"Stryker Corporation (SYK): Ansoff Matrix [June-2026 Updated]","description":"\u003cp\u003eYou get a ready-made, research-based growth strategy analysis that shows how Company Name can grow through stronger U.S. orthopaedic robotics penetration, international expansion, new robotic-enabled products, and selective diversification into vascular, digital, and adjacent medtech areas. It helps you quickly see the main growth levers, such as recurring consumables, hospital workflow platforms, EU MDR-compliant launches, ambulatory surgery center solutions, and tuck-in M\u0026amp;A, while also highlighting the key execution risks around regulation, competition, and capital deployment.\u003c\/p\u003e\u003ch2\u003eStryker Corporation - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$22.6B\u003c\/strong\u003e 2024 net sales, \u003cstrong\u003e$20.5B\u003c\/strong\u003e 2023 net sales, \u003cstrong\u003e$18.4B\u003c\/strong\u003e 2022 net sales, and \u003cstrong\u003e1,000,000\u003c\/strong\u003e Mako procedures in 2022 frame Stryker Corporation's market penetration in orthopaedics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$18.4B\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$20.5B\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$22.6B\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales increase\u003c\/td\u003e\n\u003ctd\u003e$2.1B\u003c\/td\u003e\n\u003ctd\u003e2022 to 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales increase\u003c\/td\u003e\n\u003ctd\u003e$2.1B\u003c\/td\u003e\n\u003ctd\u003e2023 to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMako procedures\u003c\/td\u003e\n\u003ctd\u003e1,000,000\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMako launch year\u003c\/td\u003e\n\u003ctd\u003e2006\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWright Medical acquisition value\u003c\/td\u003e\n\u003ctd\u003e$4.7B\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022 to 2023 net sales growth\u003c\/td\u003e\n\u003ctd\u003e11.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 to 2024 net sales growth\u003c\/td\u003e\n\u003ctd\u003e10.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022 to 2024 net sales growth\u003c\/td\u003e\n\u003ctd\u003e22.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eGrow Mako share in U.S. total knee arthroplasty\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1,000,000\u003c\/strong\u003e Mako procedures in 2022, \u003cstrong\u003e2006\u003c\/strong\u003e launch year, and \u003cstrong\u003e18\u003c\/strong\u003e years by 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,000,000\u003c\/strong\u003e procedures\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2006\u003c\/strong\u003e launch year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e18\u003c\/strong\u003e years to 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand recurring consumables tied to installed capital equipment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$4.7B\u003c\/strong\u003e Wright Medical acquisition value in 2020, \u003cstrong\u003e$22.6B\u003c\/strong\u003e 2024 net sales, and \u003cstrong\u003e$2.1B\u003c\/strong\u003e 2023 to 2024 net sales increase.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.7B\u003c\/strong\u003e acquisition value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$22.6B\u003c\/strong\u003e 2024 net sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.1B\u003c\/strong\u003e 2023 to 2024 increase\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCross-sell orthopaedic instruments with Mako installations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1,000,000\u003c\/strong\u003e Mako procedures, \u003cstrong\u003e2022\u003c\/strong\u003e milestone year, and \u003cstrong\u003e$22.6B\u003c\/strong\u003e 2024 net sales.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,000,000\u003c\/strong\u003e procedures\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2022\u003c\/strong\u003e milestone year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$22.6B\u003c\/strong\u003e 2024 net sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDefend U.S. orthopaedic robotics leadership through surgeon training\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e1,000,000\u003c\/strong\u003e procedures in 2022, \u003cstrong\u003e2006\u003c\/strong\u003e launch year, and \u003cstrong\u003e22.8%\u003c\/strong\u003e net sales growth from 2022 to 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,000,000\u003c\/strong\u003e procedures\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2006\u003c\/strong\u003e launch year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e22.8%\u003c\/strong\u003e 2022 to 2024 net sales growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImprove margins via workflow and manufacturing recovery\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$4.2B\u003c\/strong\u003e net sales increase from 2022 to 2024, \u003cstrong\u003e11.4%\u003c\/strong\u003e growth from 2022 to 2023, and \u003cstrong\u003e10.2%\u003c\/strong\u003e growth from 2023 to 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.2B\u003c\/strong\u003e 2022 to 2024 increase\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e11.4%\u003c\/strong\u003e 2022 to 2023 growth\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e10.2%\u003c\/strong\u003e 2023 to 2024 growth\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eStryker Corporation - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\u003cp\u003eStryker reported \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e in 2023 net sales. Stryker sells in more than \u003cstrong\u003e75 countries\u003c\/strong\u003e, which makes market development depend on geography, regulation, and hospital system access as much as on product performance.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket development lever\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eRelevant factual anchor\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpand Mako and SmartHospital internationally\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVocera Communications acquisition value in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroaden EU launches under MDR-compliant pathways\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 26, 2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEU Medical Device Regulation application date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroaden EU launches under MDR-compliant pathways\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e and \u003cstrong\u003eDecember 31, 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLegacy-device transition deadlines under Regulation (EU) 2023\/607\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget ambulatory surgery centers with portable robotic systems\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 6,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMedicare-certified ambulatory surgery centers in the U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtend existing orthopaedic products into more hospital systems\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWright Medical acquisition value in 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse Inari portfolio to deepen non-U.S. vascular reach\u003c\/td\u003e\n\u003ctd\u003en.a.\u003c\/td\u003e\n\u003ctd\u003eNo disclosed Stryker amount in the available public data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand Mako and SmartHospital internationally\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e 2023 sales base gives Stryker the scale to support international rollout across more than \u003cstrong\u003e75 countries\u003c\/strong\u003e. The \u003cstrong\u003e$3.0 billion\u003c\/strong\u003e Vocera transaction in 2022 matters because SmartHospital is a hospital-system sale, not a single-department sale. That makes adoption more likely in large accounts that buy operating room, nursing workflow, and patient communication tools together.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$20.5 billion\u003c\/strong\u003e 2023 net sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMore than 75 countries\u003c\/strong\u003e in commercial reach\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e Vocera acquisition value\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroaden EU launches under MDR-compliant pathways\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEU MDR became applicable on \u003cstrong\u003eMay 26, 2021\u003c\/strong\u003e. Regulation (EU) 2023\/607 extended legacy-device transition dates to \u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e for Class III and implantable Class IIb devices and to \u003cstrong\u003eDecember 31, 2028\u003c\/strong\u003e for certain Class IIb and Class IIa devices. Those dates matter because they define when products can stay on the market while companies complete technical documentation, notified-body review, and country-level launch work.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMay 26, 2021\u003c\/strong\u003e EU MDR application date\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecember 31, 2027\u003c\/strong\u003e transition deadline for Class III and implantable Class IIb devices\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDecember 31, 2028\u003c\/strong\u003e transition deadline for certain Class IIb and Class IIa devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTarget ambulatory surgery centers with portable robotic systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe U.S. has more than \u003cstrong\u003e6,000\u003c\/strong\u003e Medicare-certified ambulatory surgery centers. That number matters because ASCs buy on footprint, throughput, and capital intensity. Portable robotic systems fit that channel better than large inpatient buildouts, especially when the same platform can support multiple procedures across one site.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMore than 6,000\u003c\/strong\u003e Medicare-certified ASCs in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$20.5 billion\u003c\/strong\u003e 2023 net sales base for funding channel expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExtend existing orthopaedic products into more hospital systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003e$4.0 billion\u003c\/strong\u003e Wright Medical acquisition in 2020 widened Stryker's orthopaedic platform in foot and ankle, upper extremities, and biologics. That scale helps in hospital-system selling because multi-site health systems usually want broader contract coverage, more standardization, and fewer vendors across trauma, reconstruction, and extremities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.0 billion\u003c\/strong\u003e Wright Medical acquisition value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e acquisition year\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eUse Inari portfolio to deepen non-U.S. vascular reach\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo disclosed Stryker amount in the available public data set gives an Inari portfolio value, non-U.S. revenue split, or country-by-country rollout number.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCalculation\u003c\/th\u003e\n\u003cth\u003eFormula\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVocera acquisition as a share of 2023 net sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e \/ \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWright Medical acquisition as a share of 2023 net sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.0 billion\u003c\/strong\u003e \/ \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined acquisition values as a share of 2023 net sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.0 billion\u003c\/strong\u003e \/ \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStryker Corporation - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\u003cp\u003eStryker Corporation reported \u003cstrong\u003e$22.6 billion\u003c\/strong\u003e in 2024 net sales. That scale makes product development central to growth because the company can sell more new devices, software, and workflow tools to the same hospital and surgeon base.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct-development area\u003c\/th\u003e\n\u003cth\u003eReal-life Stryker item\u003c\/th\u003e\n\u003cth\u003eNumber or amount\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotic-enabled orthopaedics\u003c\/td\u003e\n\u003ctd\u003eMako SmartRobotics and Mako Total Knee 2.0\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e procedure families\u003c\/td\u003e\n\u003ctd\u003eGives Stryker more ways to sell new instruments into existing orthopedic operating rooms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmartHospital platform\u003c\/td\u003e\n\u003ctd\u003eVocera Communications acquisition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.09 billion\u003c\/strong\u003e in 2022\u003c\/td\u003e\n\u003ctd\u003eAdds communication and workflow software for clinical teams\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFracture, trauma, and extremity systems\u003c\/td\u003e\n\u003ctd\u003eWright Medical acquisition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.0 billion\u003c\/strong\u003e in 2020\u003c\/td\u003e\n\u003ctd\u003eExpands foot and ankle and upper-extremity product depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined digital and orthopedic expansion\u003c\/td\u003e\n\u003ctd\u003eVocera + Wright Medical\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.09 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows the size of Stryker's product-extension bets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate scale\u003c\/td\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports launch budgets, field training, and regulatory work\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdd new robotic-enabled orthopaedic instruments\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMako SmartRobotics is built around \u003cstrong\u003e4\u003c\/strong\u003e procedure families: total knee, total hip, partial knee, and spine. Mako Total Knee 2.0 is the clearest recent upgrade in that line. Product development here matters because every new cutting guide, software update, and instrument set can deepen use inside a hospital that already owns the platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand SmartHospital platform features for clinical workflows\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStryker bought Vocera Communications for \u003cstrong\u003e$3.09 billion\u003c\/strong\u003e in 2022. That deal matters because hospital workflow software is not a one-off device sale; it ties communication, alarms, and care-team coordination to daily operations. A stronger SmartHospital platform can raise switching costs and make Stryker harder to replace in the operating room and on the ward.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLaunch more fracture, trauma, and extremity systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStryker paid \u003cstrong\u003e$4.0 billion\u003c\/strong\u003e for Wright Medical in 2020. That transaction gave Stryker a larger foot and ankle and upper-extremity base, which supports new plates, nails, fixation tools, and related implants. The product-development logic is simple: more specialty systems let Stryker sell more implant and instrument lines to the same orthopedic surgeons.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDevelop additional patient-specific implants and enabling tech\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatient-specific implants rely on imaging, planning, and 3D manufacturing to fit anatomy more closely than standard-size implants. In Stryker's case, this is most useful when the company can pair custom implant design with robotics, navigation, and instrument planning in the same case.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntroduce new ASC-friendly lower-cost robotic solutions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eASC growth depends on lower capital cost, simpler setup, and faster turnover than hospital-based surgery. Stryker's product-development challenge is to keep the accuracy of robotic orthopedics while reducing the cost burden for outpatient sites of care.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e$7.09 billion\u003c\/strong\u003e divided by \u003cstrong\u003e$22.6 billion\u003c\/strong\u003e equals about \u003cstrong\u003e31%\u003c\/strong\u003e of 2024 net sales.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e Mako procedure families give Stryker a base for instrument and software refreshes\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.09 billion\u003c\/strong\u003e was spent on Vocera in 2022 to strengthen clinical workflow tools\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.0 billion\u003c\/strong\u003e was spent on Wright Medical in 2020 to widen extremity coverage\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.09 billion\u003c\/strong\u003e is the combined value of those two acquisitions\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$22.6 billion\u003c\/strong\u003e in 2024 net sales supports ongoing product launches and training\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eStryker Corporation - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2023 net sales:\u003c\/strong\u003e \u003cstrong\u003e$20.5 billion\u003c\/strong\u003e. \u003cstrong\u003eWright Medical:\u003c\/strong\u003e \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e. \u003cstrong\u003eVocera Communications:\u003c\/strong\u003e \u003cstrong\u003e$3.0 billion\u003c\/strong\u003e. \u003cstrong\u003eK2M:\u003c\/strong\u003e \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e. \u003cstrong\u003eInvuity:\u003c\/strong\u003e \u003cstrong\u003e$190 million\u003c\/strong\u003e. \u003cstrong\u003ePhysio-Control:\u003c\/strong\u003e \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e. \u003cstrong\u003eNovadaq:\u003c\/strong\u003e \u003cstrong\u003e$701 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBuild cardiovascular IVL from the AVS acquisition\u003c\/strong\u003e AVS: not publicly disclosed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand into new vascular intervention segments\u003c\/strong\u003e Endovascular, neurovascular, and vascular-adjacent medtech exposure: not publicly disclosed in a single AVS transaction amount.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMove further into hospital digital transformation services\u003c\/strong\u003e Vocera Communications: \u003cstrong\u003e$79.25\u003c\/strong\u003e per share; approximately \u003cstrong\u003e$3.0 billion\u003c\/strong\u003e enterprise value; \u003cstrong\u003e2022\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePursue tuck-in M\u0026amp;A in adjacent medtech categories\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWright Medical\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$30.75\u003c\/strong\u003e per share; approximately \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExtremities, foot and ankle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVocera Communications\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$79.25\u003c\/strong\u003e per share; approximately \u003cstrong\u003e$3.0 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHospital communication and workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eK2M\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$27.50\u003c\/strong\u003e per share; approximately \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSpine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvuity\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.40\u003c\/strong\u003e per share; approximately \u003cstrong\u003e$190 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSurgical illumination and retraction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysio-Control\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEmergency care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovadaq\u003c\/td\u003e\n\u003ctd\u003e2017\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$701 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSurgical imaging\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eEnter new procedure areas beyond core orthopaedics\u003c\/strong\u003e \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e Wright Medical, \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e K2M, and \u003cstrong\u003e$190 million\u003c\/strong\u003e Invuity.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.4 billion\u003c\/strong\u003e Wright Medical\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.4 billion\u003c\/strong\u003e K2M\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$190 million\u003c\/strong\u003e Invuity\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.5 billion\u003c\/strong\u003e Physio-Control\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$701 million\u003c\/strong\u003e Novadaq\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45497913376917,"sku":"syk-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/syk-ansoff-matrix.png?v=1740218714","url":"https:\/\/dcf-model.com\/pt\/products\/syk-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}